Clinicopathologic and molecular characterization of melanomas mutated for CTNNB1 and MAPK.


Journal

Virchows Archiv : an international journal of pathology
ISSN: 1432-2307
Titre abrégé: Virchows Arch
Pays: Germany
ID NLM: 9423843

Informations de publication

Date de publication:
Feb 2022
Historique:
received: 28 10 2020
accepted: 09 05 2021
revised: 04 05 2021
pubmed: 21 5 2021
medline: 9 4 2022
entrez: 20 5 2021
Statut: ppublish

Résumé

Wnt/β-catenin signaling plays crucial roles in melanocyte biology and may be implicated in melanoma progression. In this study, we retrospectively examined a real-life cohort of melanomas mutated for β-catenin (CTNNB1), in association or not with a MAPK mutation (of BRAF or NRAS), and analyzed their clinical, histopathological, and molecular characteristics. Our results indicate that, regardless of the presence of a concurrent MAPK mutation, CTNNB1

Identifiants

pubmed: 34013383
doi: 10.1007/s00428-021-03119-0
pii: 10.1007/s00428-021-03119-0
doi:

Substances chimiques

CTNNB1 protein, human 0
beta Catenin 0
Proto-Oncogene Proteins B-raf EC 2.7.11.1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

475-480

Informations de copyright

© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Références

Nusse R, Clevers H (2017) Wnt/β-catenin signaling, disease, and emerging therapeutic modalities. Cell 169:985–999. https://doi.org/10.1016/j.cell.2017.05.016
doi: 10.1016/j.cell.2017.05.016 pubmed: 28575679
Hari L, Brault V, Kléber M et al (2002) Lineage-specific requirements of β-catenin in neural crest development. J Cell Biol 159:867–880. https://doi.org/10.1083/jcb.200209039
doi: 10.1083/jcb.200209039 pubmed: 12473692 pmcid: 2173383
Dunn KJ, Williams BO, Li Y, Pavan WJ (2000) Neural crest-directed gene transfer demonstrates Wnt1 role in melanocyte expansion and differentiation during mouse development. Proc Natl Acad Sci U S A 97:10050–10055. https://doi.org/10.1073/pnas.97.18.10050
doi: 10.1073/pnas.97.18.10050 pubmed: 10963668 pmcid: 34553
Gao C, Wang Y, Broaddus R et al (2018) Exon 3 mutations of CTNNB1 drive tumorigenesis: a review. Oncotarget 9:5492–5508. https://doi.org/10.18632/oncotarget.23695
doi: 10.18632/oncotarget.23695 pubmed: 29435196
Palmieri G, Colombino M, Casula M et al (2018) Molecular pathways in melanomagenesis: what we learned from next-generation sequencing approaches. Curr Oncol Rep 20:86. https://doi.org/10.1007/s11912-018-0733-7
doi: 10.1007/s11912-018-0733-7 pubmed: 30218391 pmcid: 6153571
Delmas V, Beermann F, Martinozzi S et al (2007) Beta-catenin induces immortalization of melanocytes by suppressing p16INK4a expression and cooperates with N-Ras in melanoma development. Genes Dev 21:2923–2935. https://doi.org/10.1101/gad.450107
doi: 10.1101/gad.450107 pubmed: 18006687 pmcid: 2049194
Damsky WE, Curley DP, Santhanakrishnan M et al (2011) β-catenin signaling controls metastasis in Braf-activated Pten-deficient melanomas. Cancer Cell 20:741–754. https://doi.org/10.1016/j.ccr.2011.10.030
doi: 10.1016/j.ccr.2011.10.030 pubmed: 22172720 pmcid: 3241928
Chien AJ, Moore EC, Lonsdorf AS et al (2009) Activated Wnt/ss-catenin signaling in melanoma is associated with decreased proliferation in patient tumors and a murine melanoma model. Proc Natl Acad Sci 106:1193–1198. https://doi.org/10.1073/pnas.0811902106
doi: 10.1073/pnas.0811902106 pubmed: 19144919 pmcid: 2626610
Birkeland E, Zhang S, Poduval D et al (2018) Patterns of genomic evolution in advanced melanoma. Nat Commun 9:2665. https://doi.org/10.1038/s41467-018-05063-1
doi: 10.1038/s41467-018-05063-1 pubmed: 29991680 pmcid: 6039447
Biechele TL, Kulikauskas RM, Toroni RA et al (2012) Wnt/ -catenin signaling and AXIN1 regulate apoptosis triggered by inhibition of the mutant kinase BRAFV600E in human melanoma. Sci Signal 5:ra3. https://doi.org/10.1126/scisignal.2002274
doi: 10.1126/scisignal.2002274 pubmed: 22234612 pmcid: 3297477
Spranger S, Bao R, Gajewski TF (2015) Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity. Nature 523:231–235. https://doi.org/10.1038/nature14404
doi: 10.1038/nature14404 pubmed: 25970248
Yeh I, Lang UE, Durieux E et al (2017) Combined activation of MAP kinase pathway and β-catenin signaling cause deep penetrating nevi. Nat Commun 8:644. https://doi.org/10.1038/s41467-017-00758-3
doi: 10.1038/s41467-017-00758-3 pubmed: 28935960 pmcid: 5608693
de la Fouchardière A, Caillot C, Jacquemus J et al (2019) β-Catenin nuclear expression discriminates deep penetrating nevi from other cutaneous melanocytic tumors. Virchows Arch 474:539–550. https://doi.org/10.1007/s00428-019-02533-9
doi: 10.1007/s00428-019-02533-9 pubmed: 30756182
Hoek KS, Schlegel NC, Brafford P et al (2006) Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. Pigment Cell Res 19:290–302. https://doi.org/10.1111/j.1600-0749.2006.00322.x
doi: 10.1111/j.1600-0749.2006.00322.x pubmed: 16827748
Hoek KS, Eichhoff OM, Schlegel NC et al (2008) In vivo switching of human melanoma cells between proliferative and invasive states. Cancer Res 68:650–656. https://doi.org/10.1158/0008-5472.CAN-07-2491
doi: 10.1158/0008-5472.CAN-07-2491 pubmed: 18245463

Auteurs

Bénédicte Oulès (B)

Department of Dermatology and Centre D'investigation Clinique (CIC), Assistance Publique-Hôpitaux de Paris (AP-HP), Saint Louis Hospital, 75010, Paris, France.
Institut Cochin, Cutaneous Biology Lab, INSERM U1016, UMR8104, Université de Paris, 75014, Paris, France.
Department of Dermatology, Assistance Publique-Hôpitaux de Paris (AP-HP), Cochin Hospital, 75006, Paris, France.

Samia Mourah (S)

Department of Pharmacology and Tumor Genomics, Assistance Publique-Hôpitaux de Paris (AP-HP), Saint Louis Hospital, 75010, Paris, France.
Université de Paris, INSERM UMRS 976, 75010, Paris, France.

Barouyr Baroudjian (B)

Department of Dermatology and Centre D'investigation Clinique (CIC), Assistance Publique-Hôpitaux de Paris (AP-HP), Saint Louis Hospital, 75010, Paris, France.

Fanélie Jouenne (F)

Department of Pharmacology and Tumor Genomics, Assistance Publique-Hôpitaux de Paris (AP-HP), Saint Louis Hospital, 75010, Paris, France.
Université de Paris, INSERM UMRS 976, 75010, Paris, France.

Julie Delyon (J)

Department of Dermatology and Centre D'investigation Clinique (CIC), Assistance Publique-Hôpitaux de Paris (AP-HP), Saint Louis Hospital, 75010, Paris, France.
Université de Paris, INSERM UMRS 976, 75010, Paris, France.

Baptiste Louveau (B)

Department of Pharmacology and Tumor Genomics, Assistance Publique-Hôpitaux de Paris (AP-HP), Saint Louis Hospital, 75010, Paris, France.
Université de Paris, INSERM UMRS 976, 75010, Paris, France.

Aurélia Gruber (A)

Department of Pharmacology and Tumor Genomics, Assistance Publique-Hôpitaux de Paris (AP-HP), Saint Louis Hospital, 75010, Paris, France.
Université de Paris, INSERM UMRS 976, 75010, Paris, France.

Céleste Lebbé (C)

Department of Dermatology and Centre D'investigation Clinique (CIC), Assistance Publique-Hôpitaux de Paris (AP-HP), Saint Louis Hospital, 75010, Paris, France.
Université de Paris, INSERM UMRS 976, 75010, Paris, France.

Maxime Battistella (M)

Université de Paris, INSERM UMRS 976, 75010, Paris, France. maxime.battistella@aphp.fr.
Department of Pathology, Assistance Publique-Hôpitaux de Paris (AP-HP), Saint Louis Hospital, 75010, Paris, France. maxime.battistella@aphp.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH